Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Diagnostics › Molecular Diagnostics › SAT Developing Longitudinal Protein Panel Using Mass Spec, Dried Blood Spots

SAT Developing Longitudinal Protein Panel Using Mass Spec, Dried Blood Spots

Jul 21, 2016
|
Adam Bonislawski
Premium

NEW YORK (GenomeWeb) – Clinical proteomics firm SISCAPA Assay Technologies is developing a 12-protein panel for longitudinal tracking of cardiovascular disease, kidney disease, and diabetes.

The panel will use mass spec-based analysis of dried blood spot samples, which should improve patient convenience and lower costs, SAT CEO Leigh Anderson told GenomeWeb. He added that the company is currently in discussions with several large clinical reference labs about possibly implementing the panel as a CLIA test.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Jun
04
Featured Webinar

COVID-19 Testing, Treatment and Future Outlook

Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

Jul
15
Featured Webinar

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

What's Popular?

In Molecular Diagnostics

  1. LetsGetChecked At-Home Molecular SARS-CoV-2 Test Nabs FDA Emergency Use Authorization

  2. AMP SARS-CoV-2 Molecular Dx Survey Shows Supply Chain Issues Hampered Ramp Up of Testing

  3. FDA Releases Reference Panel for Coronavirus Test Developers

  4. Progenity Files for IPO, Seeks to Raise up to $100M

  5. With Low-Cost SARS-CoV-2 Assay, FYR Diagnostics Looks to Bypass Equipment Bottlenecks

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.